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Abstract
Background: The Freezing of Gait Questionnaire (FOGQ) was developed in response to the difficulties of observing
and quantifying freezing of gait (FOG) clinically as well as in laboratory settings. However, as the FOGQ is a
clinician-administered patient-reported rating scale it cannot be used in postal surveys. Here we report the
development and measurement properties of a self-administered version of the FOGQ (FOGQsa).
Methods: A clinical sample and a postal survey sample of non-demented people with Parkinson’s disease (PD;
total n = 225) completed the FOGQsa and questionnaires concerning physical functioning (PF) and fall-related self
efficacy (FES). Additional questions (No/Yes) regarded previous falls and whether they were afraid of falling. The
clinical sample was also assessed with the Unified PD Rating Scale (UPDRS). Thirty-five participants completed
FOGQsa and were also assessed with the original version (FOGQ) in a clinical interview.
Results: There were no differences (P = 0.12) between FOGQ (median, 10; q1-q3, 2-14) and FOGQsa (median, 8; 2-
14) scores. The Spearman (rs) and intra-class correlations between the two were 0.92 and 0.91 (95% CI, 0.82-0.95),
respectively. For FOGQsa, corrected item-total correlations ranged between 0.68-0.89. Reliability was 0.93 (95% CI,
0.91-0.94). FOGQsa scores correlated strongest with UPDRS Item 14 (Freezing; rs, 0.76) and with FES (rs, -0.74). The
weakest correlation was found with age (rs, 0.14). Fallers scored significantly (p < 0.001) higher on FOGQsa
compared to non-fallers, median scores 8 (q1-q3, 4-14) versus 2 (0-7). Those expressing a fear of falling scored
higher (p < 0.001) than those who did not, median scores 2 (0-7) versus 6 (2-14).
Conclusions: The present findings indicate that the FOGQsa is as reliable and valid as the original interview
administered FOGQ version. This has important clinical implications when investigating FOG in large scale studies.
Background
Up to 50% of people with Parkinson’s disease (PD)
experience sudden and transient motor blocks (freezing)
while initiating or performing activities [1]. Freezing of
gait (FOG) is often described as if the feet are glued to
the ground [1,2]. This description is recommended to
use when asking people with PD about the phenomenon
[3]. FOG typically appears when initiating the first step
(start hesitation), on turning or when approaching a tar-
get (destination hesitation or “target freezing”) [1,2].
FOG is usually evoked in crowded and confined spaces
as well as in time limiting situations, e.g., when crossing
a street [1,2,4-7].
The presence and severity of FOG has been found to
be associated with longer disease duration [1,7,8], more
advanced disease stage [1,7,8], falls [6,9-13], dyskinesias
[1] and decreased mobility [14]. FOG is in fact one of
the most distressing symptoms in PD [15], and it has a
negative impact on patient perceived health [14,16].
FOG is characterized by its unpredictable and episodic
nature. It typically occurs as short lasting episodes at
home, which makes it difficult to observe and quantify
during clinical testing as well as in laboratory settings
[17,18]. Evaluating FOG is commonly done by either
posing a question or by using a single item assessment
such as item 14 of the Unified PD Rating Scale
(UPDRS) [8-10,13]. Therefore, Giladi et al. developed
the Freezing of Gait Questionnaire (FOGQ) which is a
clinician/interview administer e dp a t i e n t - r e p o r t e dr a t i n g
scale [19]. The FOGQ consists of six items scored from
0-4. The total score ranges from 0 to 24, and higher
scores denote more severe FOG. * Correspondence: Maria_H.Nilsson@med.lu.se
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bach’s alpha, 0.94) and validity in 40 people with PD
[19]. However, although the FOGQ appears to be a use-
ful and valid tool for its purpose, the dependency on a
clinician to interview the patient and to demonstrate the
meaning of FOG is also limiting. For example, the tool
becomes somewhat time consuming for implementation
in clinical practice and cannot be used for larger scale
postal surveys. A completely self-administered FOGQ
scale that provides the same type of information would
therefore be of great benefit.
This study assessed the validity and reliability of a self-
administered version of the FOGQ, i.e. the FOGQsa. In
addition, we explored the relationships between
FOGQsa scores and patient demographics, fear of fall-
ing, falls, gait, motor complications and physical
functioning.
Methods
The study was divided into two phases: (1) development
of a self-administered version of FOGQ (the FOGQsa)
and (2) testing the psychometric properties of the
FOGQsa.
Development of the FOGQsa
The intention was to preserve the semantic content of
all six original FOGQ items but with revisions of the
wording to make them applicable for self-administra-
tion. In accordance with the original FOGQ instrument
[19], responses should be based on experiences over the
last week except for item 3. As in the original FOGQ
scale, all items are scored from 0-4 (possible total score
range, 0-24; higher scores = more severe FOG).
To substitute for the demonstration and description of
FOG in the FOGQ, a cover sheet explaining the FOG
phenomenon was developed for the FOGQsa. The
description was based on a review of the literature, and
it was constructed in close interaction with two nurses
and two neurologists specialized in PD. The cover sheet
describes that FOG is typically experienced as if “the
feet are glued to the ground”, and that this can happen
while trying to initiate walking, while walking (which
could be accompanied by taking smaller and smaller
steps) or while turning. Other provocative factors are
also described such as walking in confined spaces (e.g.
passing a doorway), target hesitation (e.g. just before
approaching a chair when sitting down) and when hav-
ing limited time (e.g. crossing a street) [1,2,4-7].
Following modification of the FOGQ into the
FOGQsa, face-to-face field-test interviews were con-
ducted with 14 non-demented people with PD (9 men)
with varying degrees of motor complications and/or gait
disturbances to assess clarityo fw o r d i n g ,f a c ev a l i d i t y
and respondent burden.
Psychometric properties of the FOGQsa
Participants
Data collection included a clinical sample and a postal
survey sample of non-demented people with idiopathic
PD [20].
The clinical sample consisted of a convenience sample
with varying degrees of motor complications and/or gait
disturbances receiving out-patient care at a Swedish uni-
v e r s i t yh o s p i t a l( T a b l e1 ) .F i f t yp a t i e n t sw e r ei n v i t e dt o
participate. Eight patients declined participation and five
patients were unable to attend the study appointment.
An additional participant did not complete the FOGQsa
and was therefore excluded. Thus, 36 participants were
included.
The postal survey sample was recruited from another
S w e d i s hu n i v e r s i t yh o s p i t a l( T a b l e1 ) .T h es u r v e yw a s
sent to 282 patients (39% female), and 231 were
returned, of which 191 were completed (43% female;
conservative total response rate, 68%). Thirty-eight ques-
tionnaires were returned completely blank and two were
returned to sender due to change of address. Out of the
191 responders, two had left all items of the FOGQsa
blank. These two participants were excluded, leaving
189 participants for analyses. Demographic data of all
225 participants are presented in Table 1.
Instruments
All participants completed the FOGQsa, the Swedish
version of the Falls-Efficacy Scale, FES(S) [21], and the
Physical Functioning (PF) scale of the Medical Out-
comes Study 36-Item Short-Form Health Survey (SF-36)
[22].
FES(S) assesses fall-related self-efficacy, and the 13
activities are rated from 0 (not confident at all) to 10
(completely confident) [21]. The total score can range
f r o m0t o1 3 0 .P Fc o m p r i s e st e ni t e m sa b o u tp h y s i c a l
activities [22]. The score can range from 0 to 100,
where higher scores denote better physical functioning.
Additional questions included whether participants had
fallen during the past six months (No/Yes) and if they
were afraid of falling (No/Yes). The clinical sample was
also asked whether they felt unsteady while turning
(No/Yes).
Procedure
The FOGQsa was mailed to the clinical sample before
the study visit. The participants were instructed to com-
plete it three days before the visit, put the completed
questionnaire in an envelope, seal it and bring it to the
study visit. Demographic data (Table 1) were collected
through self report for all participants, which the clinical
sample completed at their out-patient visit. Demographic
questions preceded the included self-administered ques-
tionnaires. In addition, the clinical sample was assessed
with timed gait tests: ten meter walk test (gait speed,
both comfortable and fast) and Timed Up & Go (TUG).
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The FOGQ was thereafter administered as a clinical
interview including a demonstration of FOG [19]. That
is, the assessor demonstrated typical manifestations of
start hesitation, freezing at the doorway and while turn-
ing. Finally, clinical assessments according to the UPDRS
and Hoehn & Yahr stages (HY) [23] were conducted by
an independent assessor who was unaware of previous
test results. HY was also assessed for the “off” phase
based on patient-reported history. In the postal survey
sample, self administered versions of UPDRS items 13
(falling), 14 (freezing) and 15 (walking) were included
[24]. All participants of the postal survey sample received
a reminder about ten days after the first administration.
The study was reviewed by the local ethics advisory
committee, and the included participants gave their
written informed consent.
Analyses The primary aim of the analyses was to
explore to what extent the FOGQsa scores reproduced
the findings of the original FOGQ instrument [7,19,25].
We thus explored whether the assumptions for sum-
ming FOGQsa item scores into a total score were met
[26]. That is, we examined whether item mean scores
and standard deviations were roughly similar and if the
corrected item-total correlations exceeded 0.3. Whether
the items appear to represent a common variable was
considered supported if corrected item-total correlations
were ≥0.4 [26].
Table 1 Participants’ characteristics
Total sample
n = 225
Clinical sample
n=3 6
Postal survey
n = 189
Mean age, years (SD, min.-max.) 69.1 (8.9) 65.3 (6.2) 69.9 (9.1)
42.0-91.0 49.0-83.0 42.0-91.0
n = 221 n = 36 n = 185
Mean PD-duration, years (SD, min.-max.) 7.7 (6.8) 14.6 (8.3) 6.2 (5.5)
0.33-44.0 2.2-44.0 0.33-28.0
n = 210 n = 36 n = 174
Gender (men/women), n (%) 137 (62%)/ 29 (81%)/ 108 (58%)/
84 (38%) 7 (19%) 77 (42%)
n = 221 n = 36 n= 185
Falls past 6 months (yes/no), n (%) 88 (40%)/ 19 (53%)/ 69 (38%)/
131 (60%) 17 (47%) 114 (62%)
n = 219 n = 36 n = 183
Fear of falling (yes/no), n (%) 94 (43%)/ 9 (25%)/ 85 (46%)/
125 (57%) 27 (75%) 98 (54%)
n = 219 n = 36 n = 183
Median, q1-q3 Median, q1-q3 Median, q1-q3
Falls-Efficacy Scale (S) 112.0 106.5 114.0
75.0-130.0 94.8-129.0 69.0-130.0
n = 183 n = 30 n = 153
Physical Functioning (PF, SF-36) 55.0 24.0 60.0
29.0-75.0 20.0-28.0 35.0-80.0
n = 218 n = 30 n = 188
Item 13, UPDRS II (Falling) 0.0 0.0 0.0
0.0-1.0 0.0-1.0 0.0-1.0
n = 223 n = 36 n = 187
Item 14, UPDRS II (Freezing) 0.0 0.0 0.0
0.0-1.0 0.0-1.8 0.0-1.0
n = 221 n = 36 n = 185
Item 15, UPDRS II (Walking) 1.0 1.0 1.0
0.0-2.0 0.0-1.0 0.0-2.0
n = 221 n = 34 n = 187
Falls-Efficacy Scale, Swedish version; the total score can range between 0-130 (higher scores = better).
Physical Functioning (PF, SF-36); total score range between 0-100 (higher scores = better).
Item 13, 14 and 15 of the UPDRS part II; each item graded from 0-4 (higher scores = greater severity).
Additional data regarding the participants are presented in Table 3.
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obtaining minimum and maximum scores, respectively)
were examined, and should be <15-20% [27,28]. Reliabil-
ity (Cronbach’s alpha) was also estimated, and should be
≥0.8 [29]. In addition, the standard error of measure-
ment (SEM) was estimated using the formula:
SEM SD 1  =× − √() 
Using data from the clinical sample, we assessed the
relationship between the original FOGQ and the
FOGQsa through Spearman (rS) and intra-class correla-
tions (ICC; one-way random model). The correlations
were expected to be strong (>0.8) in order to support
criterion-related validity. Construct validity was assessed
by examining the pattern of correlations (rS) between
FOGQsa and UPDRS scores. To replicate the patterns
reported for the original version of FOGQ [19,25], the
correlation with FOGQsa scores was expected to be
strongest for UPDRS part II (Activities of Daily Living,
ADL) and weakest for UPDRS part I (mentation, beha-
vior and mood) [7,19,25]. Among individual UPDRS
items, we expected a stronger correlation between
FOGQsa scores and item 14 (freezing) than with items
13 (falling unrelated to freezing), 15 (walking), 29 (gait)
and 30 (postural stability) [19,25]. The correlation with
disease severity (HY) was expected to be stronger in the
“off” state than in the “on” state [25].
In addition, we examined the relationships between
FOGQsa scores and patient demographics, FES(S),
timed gait tests, dyskinesias (items 32-35 of the UPDRS
part IV), motor fluctuations (items 36-39 of the UPDRS
part IV) and PF. We expected the FOGQsa scores to
correlate stronger with dyskinesia, motor fluctuations
and FES(S) scores than with gait tests [25]. The weakest
correlation was expected with age [25]. We also assessed
differences (Mann-Whitney U test) in FOGQsa scores
between people who did and did not report falls, fear of
falling and unsteadiness while turning. It was expected
that fallers, those reporting fear of falling and those
being unsteady while turning would score higher.
Analyses were performed using SPSS 15 (SPSS Inc.,
Chicago, IL) and ScoreRelCI (Barnette 2005). Two-tailed
p-values <0.05 were considered statistically significant.
P-values were not corrected for multiple testing.
Results
Field-test participants had a mean age of 64 (SD, 5.2)
years and an average PD-duration of 16 (SD, 5.5) years.
All 14 participants found the description of FOG to be
clear and understandable and items were considered
relevant and easy to answer. One participant commen-
ted that the duration of freezing was somewhat difficult
to estimate. Two comments related to the frequency of
freezing. However, no changes in the questionnaire were
deemed necessary due to these comments. The mean
time for completing FOGQsa was 3 (SD, 1.3) minutes.
For the total sample, mean and SD for FOGQsa items
scores ranged between 0.76-1.6 and 1.1-1.4, respectively
(Table 2). Corrected item-total correlations ranged
between 0.68-0.89. Forty-one participants (19%) scored
0, and none reached the maximum score of 24. Reliabil-
ity was 0.93 (95% CI, 0.91-0.94), and SEM was 1.6.
Results for the two subsamples were similar (Table 2).
Total FOGQsa scores could be computed for 214 (95%)
out of the 225 participants.
Data for both the FOGQsa and the original FOGQ
were available for 35 people in the clinical sample.
There were no differences (P = 0.12) between FOGQ
(median, 10; q1-q3, 2-14) and FOGQsa (median, 8; q1-
q3, 2-14) scores. The Spearman and intra-class correla-
tions were 0.92 and 0.91 (95% CI, 0.82-0.95), respec-
tively (Figure 1). The mean number of days between
completions was 2.6 (SD, 0.80).
The relationships between FOGQsa scores and other
variables are presented in Table 3. The FOGQsa scores
for the total sample showed the strongest correlation
with UPDRS item 14 (Freezing; rs, 0.76) and with FES(S)
(rs, -0.74). The weakest correlation was found with age
(rs, 0.14). For common variables, both samples showed
similar patterns (Table 3). However, the clinical sample
showed a stronger correlation with UPDRS part II (rs,
0.68) than with FES(S) (rs, -0.57) (Table 3).
FOGQsa scores did not differ (p > 0.3) between gen-
ders. For the total sample, the median score was 4 for
both women and men (q1-q3, 1-9 and 1-11, respectively).
Out of the 225 participants, 219 responded to the ques-
tion whether they had fallen during the past six months.
Fallers (88/219; 40%) scored significantly (p < 0.001)
higher on FOGQsa compared to non-fallers, median
scores 8 (q1-q3, 4-14) versus 2 (q1-q3, 0-7). Those
expressing a fear of falling scored higher (p < 0.001) than
those who did not, median scores 2 (q1-q3, 0-7) versus 6
( q 1 - q 3 ,2 - 1 4 ) .I nt h ec l i n i c a ls a m p l e ,t h o s er e p o r t i n g
unsteadiness while turning (20/35; 57%) had significantly
(p = 0.030) higher FOGQsa scores than those who did
not, median scores 11 (q1-q3, 6-16) versus 2 (0-13).
Discussion
The present findings indicate that the FOGQsa is as
reliable and valid as the original interview administered
FOGQ version. Specifically, our observations support
the legitimacy of summing item scores into a reliable
total score that corresponds closely to FOGQ scores. In
addition, construct validity is supported by a correlation
pattern very similar to that reported for the original
FOGQ version. This has important clinical implications
when investigating FOG.
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not include provocative circumstances of FOG [3].
When using a self-administered assessment it is crucial
that the investigated construct is well defined and
described. The cover sheet of the FOGQsa was created
in order to make certain that the individual recognizes
and fully understands the investigated phenomenon. It
therefore included both environmental and circumstan-
tial factors that may provoke FOG; narrow space (e.g.
passing a doorway) [1,2,6,7], crowded space and limited
time, e.g. trying to cross a busy street [2,4-6]. The origi-
nal FOGQ does not mention target hesitation although
FOG is known to occur when reaching a target [1,2,4,5].
This new self administered version does, however,
include target hesitation when describing FOG. Field
testing of the FOGQsa revealed that the participants
considered the content to be both clear and relevant.
The respondent burden was marginal as indicated by a
short completion time.
FOGQsa had an internal consistency reliability above
0.90 and thus exceeded the recommendation of 0.80 [29].
This finding is similar to the results for the original
FOGQ version [7,19,25]. In a separate pilot study, we
have also found its test-retest reliability to be adequate
(ICC, 0.85) [30]. However, further studies investigating
Table 2 Descriptive and psychometric FOGQsa data
Total sample
n = 225
Clinical sample
n=3 6
Postal survey sample
n = 189
Item Mean (SD) Corrected Item-total
correlations n = 214
Mean (SD) Corrected Item-total
correlations n=3 5
Mean (SD) Corrected Item-total
correlations n = 179
1 “Walking during worst state” 1.6 (1.1)
2 missing
0.68 1.7 (1.2)
1 missing
0.87 1.6 (1.1)
1 missing
0.64
2 “Gait difficulties affecting
daily activities and
independence”
1.1 (1.1)
2 missing
0.68 1.2 (1.1)
1 missing
0.76 1.1 (1.2)
1 missing
0.68
3 “Feet getting glued to the
floor”
1.1 (1.4)
1
3 missing
0.83 1.7 (1.4) 0.82 1.0 (1.4)
2 missing
0.84
4 “Duration of longest freezing
episode”
0.87 (1.3)
7 missing
0.89 1.6 (1.6) 0.91 0.73 (1.1)
7 missing
0.90
5 “Duration of typical start
hesitation”
0.76 (1.1)
6 missing
0.88 1.2 (1.4) 0.85 0.67 (1.1)
6 missing
0.89
6 “Duration of typical turning
hesitation”
0.76 (1.1)
5 missing
0.83 1.1 (1.4) 0.78 0.68 (1.1)
5 missing
0.85
Total score
n = 214
Total score
n=3 5
Total score
n = 179
Mean (SD) 6.1 (6.2) 8.6 (7.2) 5.6 (5.9)
Median, q1-q3 4.0, 1.0-4.0 8.0, 2.0-
14.0
4.0, 1.0-9.0
Min-max 0-22 0-22 0-22
% scoring minimum
(0)/maximum (24)
19/0 17/0 20/0
Reliability, Cronbach’s alpha
(95% CI)
0.93 (0.91-0.94) 0.94 (0.90-0.97) 0.93 (0.91-0.94)
FOGQsa: Freezing of Gait Questionnaire, self administered version. Each item is scored between 0-4, and the total score thus ranges between 0-24. Higher scores
denote more severe FOG.
Some participants left certain items blank. Total scores could therefore be computed for 214 out of the 225 (95%).
1 On item 3, 126 scored 0, i.e. they never experienced freezing episodes, whereas 96 out of the 214 (45%) scored at least 1 and could be defined as “freezers”.
Out of the 96 reporting freezing episodes, 51 did so “often- about once a day” and 11 “always- whenever walking”.
Figure 1 The relationship between scores of the new self
administered version of the Freezing of gait (FOG)
questionnaire (FOGQsa) and the original interview
administered FOGQ (n = 35).
Nilsson et al. BMC Neurology 2010, 10:85
http://www.biomedcentral.com/1471-2377/10/85
Page 5 of 8its test-retest reliability are warranted. In the present
study, 19% of the participants scored 0 (best possible
score). Both FOGQ and FOGQsa consist of six items,
where four items assess FOG severity and two items con-
cern gait difficulties in general. Our results thus suggest
that about 20% of the participants had neither gait diffi-
culties nor FOG. In a study by Schrag et al., impaired gait
was reported by 75% of people with a PD-duration of at
least five years [31]. In another study, 21% out of 290
people with PD reported no gait problems [32]. The
observed floor effect (i.e. percentage scoring 0) thus
appears reasonable in the current targeted population.
Reasonable floor and ceiling effects are a prerequisite for
detection of differences [33]. Potential differences need
also to exceed the measurement error in order to indicate
at r u ec h a n g e .T h eS E Mo b s e r v e di nt h i ss t u d ys u g g e s t s
that the change in scores need to be at least 1.7 in order
to exceed the measurement error.
FOGQsa scores distinguished between fallers and non-
fallers. Both fallers and those expressing a fear of falling
had significantly higher FOGQsa scores than those not
reporting these problems. This is not surprising since
freezing is associated with falls [6,9-13]. Those who
reported being unsteady while turning also had higher
FOGQsa scores than those not reporting unsteadiness. In
a study investigating 130 persons with PD, turning around
was the factor most commonly identified to induce freez-
ing [6]. Turning is also associated with falls [9,11,34], and
falls associated with freezing are in fact more likely to
result in an injury [9]. This underlines the importance of
including an assessment of FOG when investigating falls
in people with PD. Availability of a self-administered
FOGQ may facilitate this in clinical practice.
When assessing FOG, Snijders et al. advocate combin-
ing physical examinations with more specific questions
about FOG [3]. However, this is not possible when con-
ducting postal surveys. FOGQ scores have also been
shown to correlate only weakly with timed gait tests
[25]. This indicates the need for using patient reported
tools, especially since FOG is difficult to capture during
a clinical or laboratory investigation [17,18]. The FOGQ
is then preferable to using a single item approach,
which is less reliable and less responsive to change [35].
Taken together, the present results speak in favor of
Table 3 Correlations with FOGQsa and descriptive values for clinical tests
Total sample
n = 225
Clinical sample
n=3 6
Postal survey
n = 189
rs p-value rs p-value rs p-value
Age, years 0.14 0.046 0.07 >0.3 0.21 0.006
PD-duration, years 0.42 <0.001 0.50 0.002 0.40 <0.001
Falls-Efficacy Scale -0.74 <0.001 -0.57 0.001 -0.78 <0.001
Physical Functioning (PF, SF-36) -0.61 <0.001 -0.50 0.006 -0.68 <0.001
Item 13, UPDRS II (Falling) 0.49 <0.001 0.53 0.001 0.49 <0.001
Item 14, UPDRS II (Freezing) 0.76 <0.001 0.72 <0.001 0.78 <0.001
Item 15, UPDRS II (Walking) 0.57 <0.001 0.56 0.001 0.64 <0.001
Clinical sample, n = 36 Median (q1-q3) rs p-value
UPDRS I, Mentation, behavior and mood 2.0 (0-3.0) 0.33 0.059
UPDRS II, Activities of Daily Living 7 (3.0-13.5) 0.68 <0.001
UPDRS III, Motor examination 15.0 (8.0-20.0) 0.55 0.001
Item 29, UPDRS III (Gait) 0.5 (0-1.0) 0.46 0.006
Item 30, UPDRS III (Postural stability) 1.0 (0-2.0) 0.49 0.003
Hoehn and Yahr ("on”) 3.0 (2.0-3.0) 0.44 0.009
Hoehn and Yahr ("off”) 3.0 (3.0-4.0) 0.58 <0.001
Dyskinesias (UPDRS IV, items 32-35) 2.5 (1.0-5.0) 0.63 <0.001
Motor fluctuations (UPDRS IV, items 36-39) 3.0 (1.3-3.8) 0.60 <0.001
Timed Up & Go, sec (Mean, SD) 9.7 (2.7) 0.34 0.049
Comfortable gait speed, m/s (Mean, SD) 1.32 (0.23) -0.29 0.094
Fast gait speed, m/s (Mean, SD) 1.60 (0.40) -0.33 0.055
Falls-Efficacy Scale, Swedish version; the total score can range between 0-130 (higher scores = better).
Physical Functioning (PF, SF-36); total score can range between 0-100 (higher scores = better).
Item 13, 14 and 15 of the UPDRS part II; each item graded from 0-4 (higher scores = greater severity).
UPDRS part I; total score range 0-16 (16 = greater severity). UPDRS part II; total score range 0-52 (52 = greater severity). UPDRS part III; total score range 0-108
(108 = greater severity).
Dyskinesias (UPDRS part IV, items 32-35); total score range 0-13 (13 = greater severity).
Motor fluctuations (UPDRS part IV, items 36-39); total score range 0-7 (7 = greater severity).
Nilsson et al. BMC Neurology 2010, 10:85
http://www.biomedcentral.com/1471-2377/10/85
Page 6 of 8using the FOGQsa when investigating FOG, falls and
fear of falling in survey studies.
There are some methodological concerns which need
to be taken into consideration. Demented patients were
excluded, and the clinical sample was not randomly
selected. This might affect the external validity of the
present findings. The lack of maximum scores may sug-
gest a bias towards less severe problems in the current
sample. However, the highest observed score (22) is very
close to the maximum score of 24, and the observed
rate of people scoring zero on the FOGQsa is consistent
with observations in previous studies (see above).
Furthermore, validation of the FOGQsa (as well as the
FOGQ) has been based on subjective data. Future stu-
dies may therefore consider adding ambulatory monitor-
ing of FOG [36]. Finally, the fact that FOGQ includes
two items concerning gait difficulties in general has
been criticized, and these items were therefore omitted
in a recent revised version of the FOGQ [37]. The
revised version supplies a video-demonstration of FOG,
but it is not self-administered. We have now initiated an
adaptation in order to create a self-administered version
of the revised version as well.
The Swedish FOGQsa described here can be obtained
from the corresponding author. An English language
version is under development and will also be obtainable
from the corresponding author when available.
Conclusions
In conclusion, we report the development and testing of
the FOGQsa, a self administered version of the FOGQ.
Its measurement properties are very similar to those pre-
viously reported for the FOGQ, suggesting that it is as
reliable and valid as the original interview administered
version. Importantly, FOGQsa scores do not differ from
and correlate strongly with FOGQ scores. These findings
suggest that no substantial information is lost by using
the self administered version as compared to the clinician
administered FOGQ. This facilitates the investigation of
FOG in postal surveys and clinical practice. Further stu-
dies are warranted in order to scrutinize the measure-
ment properties of the FOGQsa in more detail.
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